About Lupus Therapeutics
Lupus Therapeutics was established by the Lupus Research Alliance to advance lupus clinical research by finding more effective and safer treatments for people living with lupus. There are only three drugs specifically approved to treat lupus, a complex autoimmune disease that can affect people differently. More research is urgently needed to find personalized treatments and hopefully a cure. We are passionate about changing the course of lupus research and finding individual treatments and hopefully, a cure.
This is a strategic investment that we invite every stakeholder in the lupus community to take part in—patients, researchers and industry.
About Lupus Therapeutics
Lupus Therapeutics was established by the Lupus Research Alliance to advance lupus clinical research by finding more effective and safer treatments for people living with lupus. During the past sixty years, only two new drugs have been approved to treat lupus, a complex autoimmune disease that can affect people differently and change over time. We are passionate about changing the course of lupus research and finding individual treatments and hopefully, a cure.
This is a strategic investment that we invite every stakeholder in the lupus community to take part in—patients, researchers and industry.
About Lupus Therapeutics
Lupus Therapeutics was established to advance lupus clinical research by finding more effective and safer treatments for people living with lupus. During the past sixty years, only one new drug has been approved to treat lupus, a complex autoimmune disease that can affect people differently and change over time. We are passionate about changing the course of lupus research and finding individual treatments and hopefully, a cure.
This is an aspirational investment that we invite every stakeholder in the lupus community to take part in—patients, doctors, researchers and industry.
Executive Leadership

Saira Sheikh, MD – LuCIN Vice Chair
Dr. Saira Sheikh is trained, and board certified in Internal Medicine, Rheumatology and Allergy/Immunology. She is the Linda Coley Sewell Distinguished Professor of Medicine Rheumatology, Allergy & Immunology, the Director of the Clinical Trials Program at the UNC Thurston Arthritis Research Center, and the UNC Rheumatology Lupus Clinic.
Lupus Therapeutics Board of Directors

Kenneth Farber
Ken serves as the President and CEO of the Lupus Research Alliance. Ken is a graduate of Clark University, with a Juris Doctor from the Fordham University School of Law. He has spent 40 years in the non-profit world, working with and for voluntary health agencies and private foundations.

Daniel J Wallace MD, FACP, MACR
Dr. Wallace is a board-certified internist and rheumatologist. A Clinical Professor of Medicine at the David Geffen School of Medicine at UCLA, he is the Associate Director of the Rheumatology Fellowship Program at Cedars-Sinai Medical Center where he also serves on the Board of Governors.

Kimberly Williams
Kimberly currently serves as Director of Public Affairs and Alliance Development for Novo Nordisk, Inc., one of this nation’s largest pharmaceutical companies where her responsibilities include support for company priorities around alliance development and advocacy with Specialty patient and physician organizations.
Our Partners
















Discover our solutions
A research innovation accelerator dedicated to improving lupus treatments and advancing research toward a cure, ONLY Lupus Therapeutics has a track record of successfully collaborating with more than a dozen top global pharmaceutical companies working on lupus clinical studies.
Discover our solutions
A research innovation accelerator dedicated to improving lupus treatments and advancing research toward a cure, ONLY Lupus Therapeutics has a track record of successfully collaborating with more than a dozen top global pharmaceutical companies working on lupus clinical studies.